Galectin Therapeutics (GALT) Earnings Date, Estimates & Call Transcripts $1.28 -0.04 (-3.03%) Closing price 04:00 PM EasternExtended Trading$1.28 0.00 (0.00%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Galectin Therapeutics Latest Earnings SummaryUpcoming Q1 Earnings DateApr. 4Before Market OpensEstimatedActual EPS (Mar. 31) -$0.19 Missed By -$0.03 Consensus EPS (Mar. 31) -$0.16 Galectin Therapeutics posted Q4 2024 earnings on March 31, 2025, reporting an EPS of -$0.19, which missed analysts' consensus estimates of -$0.16 by $0.03. With a trailing EPS of -$0.73, Galectin Therapeutics' earnings are expected to decrease next year, from ($0.73) to ($0.92) per share. GALT Upcoming EarningsGalectin Therapeutics' next earnings date is estimated for Friday, April 4, 2025, based off prior year's reporting schedules. Get Galectin Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galectin Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataGALT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.GALT Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Galectin Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.24-$0.24-$0.24Q2 20251-$0.27-$0.27-$0.27Q3 20251-$0.63-$0.63-$0.63Q4 20251-$0.53-$0.53-$0.53FY 20254($1.67)($1.67)($1.67) Remove Ads Galectin Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 4/4/2025(Estimated)-------3/31/2025Q4 2024-$0.16-$0.19 -$0.03-$0.19--8/13/2024--$0.16-$0.20 -$0.04-$0.20--5/15/2024Q1 2024-$0.16-$0.19 -$0.03-$0.19--3/29/2024Q4 2023--$0.16 -$0.16-$0.16--11/13/2023Q3 2023-$0.16-$0.24 -$0.08-$0.24--8/14/2023Q2 2023-$0.21-$0.15+$0.06-$0.15--5/15/2023Q1 2023-$0.21-$0.19+$0.02-$0.19-- Galectin Therapeutics Earnings - Frequently Asked Questions When is Galectin Therapeutics's earnings date? Galectin Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, April 4th, 2025 based off last year's report dates. Learn more on GALT's earnings history. Did Galectin Therapeutics beat their earnings estimates last quarter? In the previous quarter, Galectin Therapeutics (NASDAQ:GALT) missed the analysts' consensus estimate of ($0.16) by $0.03 with a reported earnings per share (EPS) of ($0.19). Learn more on analysts' earnings estimate vs. GALT's actual earnings. How much profit does Galectin Therapeutics generate each year? Galectin Therapeutics (NASDAQ:GALT) has a recorded net income of -$41.07 million. GALT has generated -$0.73 earnings per share over the last four quarters. What is Galectin Therapeutics's EPS forecast for next year? Galectin Therapeutics's earnings are expected to decrease from ($0.73) per share to ($0.92) per share in the next year. More Earnings Resources from MarketBeat Related Companies BNTC Earnings CYRX Earnings ATXS Earnings AURA Earnings ALMS Earnings ARCT Earnings AQST Earnings SLDB Earnings GLUE Earnings TSHA Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Remove Ads This page (NASDAQ:GALT) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
